PHIO
Phio Pharmaceuticals Corp.
NASDAQ · Healthcare · Biotechnology · US
$1.09
−1.80%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 2.7M | 4.6M | 3.6M | 6.3M | 7.0M |
| Gross Profit | (2.7M) | (4.6M) | (3.6M) | (6.3M) | (7.0M) |
| Operating Expenses | |||||
| R&D Expense | 8.5M | 4.6M | 3.6M | 6.3M | 7.0M |
| SG&A Expense | 4.9M | 4.6M | 3.7M | 4.3M | 4.5M |
| General & Admin Expense | 4.9M | 4.6M | 3.7M | 4.3M | 4.5M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (2.7M) | (4.6M) | (3.6M) | (6.1M) | (7.0M) |
| Total Operating Expenses | 10.8M | 4.6M | 3.7M | 4.5M | 4.5M |
| Cost and Expenses | 13.5M | 9.2M | 7.4M | 10.8M | 11.5M |
| Operating Income (EBIT) | (13.5M) | (9.2M) | (7.4M) | (10.8M) | (11.5M) |
| Non-Operating | |||||
| Interest Income | 291.0K | — | 231.0K | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 291.0K | — | 231.0K | — | — |
| Other Non-Op Income/Expense | 570.0K | 522.0K | 237.0K | (2.0K) | (18.0K) |
| Non-Operating Income (excl Interest) | (440.0K) | (522.0K) | (237.0K) | 2.0K | 18.0K |
| EBT (Pre-Tax Income) | (12.9M) | (8.7M) | (7.2M) | (10.8M) | (11.5M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (12.9M) | (8.7M) | (7.2M) | (10.8M) | (11.5M) |
| Earnings from Cont. Ops | (12.9M) | (8.7M) | (7.2M) | (10.8M) | (11.5M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (12.9M) | (8.7M) | (7.2M) | (10.8M) | (11.5M) |
| Per Share | |||||
| Basic EPS | ($1.34) | ($1.45) | ($0.91) | ($46.87) | ($89.61) |
| Diluted EPS | ($1.34) | ($1.45) | ($0.91) | ($46.76) | ($89.61) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 11.6M | 6.0M | 787466 | 231000 | 126159 |
| Diluted Shares Outstanding | 11.6M | 6.0M | 787466 | 231508 | 126159 |
| Profitability Metrics | |||||
| EBITDA | (13.0M) | (8.7M) | (7.1M) | (10.6M) | (11.4M) |
| D&A | 5.0K | 3.0K | 2.0K | 184.0K | 71.0K |
| EBIT | (13.0M) | (8.7M) | (7.2M) | (10.8M) | (11.5M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026